Novartis said its challenge to Indian patent law over the country's rejection of a patent on the best-selling cancer treatment Gleevec was turned down by a court.
The Swiss company challenged India's legal basis for the rejection of a patent on Gleevec. The Indian government last year denied the application, saying the drug was insufficiently innovative. Novartis said it probably won't appeal yesterday's decision to the country's supreme court.
Novartis said that strong patent laws would strengthen Indian research. The High Court in Chennai deferred to the World Trade Organization to settle whether India was meeting international trade rules.
Doctors Without Borders and other groups contend a court victory by the drug maker would have dried up a major source of affordable medicines for people across the globe.
No comments:
Post a Comment